Fig. 6
Cyclin-dependent kinases 4/6 (CDK4/6) inhibitor synergizes with epidermal growth factor receptor (EGFR) inhibitor to suppress triple-negative breast cancer (TNBC) tumor growth. a, Top: Representative pictures of clonogenic assay showing the inhibition of tumor progression in TNBC cell lines. Bottom: Quantification of the clonogenic assay. b Representative pictures of immunohistochemistry (IHC) staining showing death effector ___domain-containing DNA-binding protein (DEDD) expression and subcellular localization in TNBC xenografts and patient-derived xenograft (PDX) samples. c Quantification of DEDD expression from IHC staining. d Comparison of HCC1806 xenograft tumor volumes within mice treated with vehicle, lapatinib (LAP) (2 mg/per mouse per day), abemaciclib (ABE) (0.5 mg/per mouse per day) and the Combo treatment; n > 10 for each treatment group. e Representative pictures of IHC staining showing Ki-67 and cleaved caspase-3 expression in different treatment groups in HCC1806 xenografts. f Quantification of IHC staining in e. g Comparison of PDX tumor volumes from mice treated with vehicle, LAP (2 mg/per mouse per day), ABE (0.5 mg/per mouse per day), and the Combo; n > 3 for each treatment group. h Representative pictures of IHC staining showing Ki-67 and cleaved caspase-3 expression in different treatment groups in PDX. i Quantification of IHC staining in h. All quantitative data were generated from a minimum of three replicates. P values were derived from one-way analysis of variance (ANOVA) with multiple comparison. Error bars represent means ± s.e.m.
